Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
09. Dezember 2024 21:00 ET
|
Lyell Immunopharma, Inc
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior...
New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting
09. Dezember 2024 07:00 ET
|
Secura Bio
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell lymphoma Results...
Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting
09. Dezember 2024 07:00 ET
|
Secura Bio
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response (DOR) of 7.89 months The...
EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting
05. Dezember 2024 20:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
26. November 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
05. November 2024 09:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
05. November 2024 09:05 ET
|
Agios Pharmaceuticals, Inc.
Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
12. Januar 2024 08:45 ET
|
International Myeloma Foundation
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at ASH 2023
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
09. Dezember 2023 20:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
09. Dezember 2023 19:00 ET
|
Agios Pharmaceuticals, Inc.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition